Acquired Rifampicin Resistance in Thrice-Weekly Antituberculosis Therapy: Impact of HIV and Antiretroviral Therapy

Abstract

HIV-infected patients with tuberculosis treated with a thrice-weekly antituberculosis regimen are at a higher risk of ARR, compared with HIV-uninfected patients, in the presence of baseline isoniazid resistance. HAART reduces but does not eliminate the risk of ARR.